Sarah Kimuda

ORCID: 0009-0002-1335-9787
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antifungal resistance and susceptibility
  • Fungal Infections and Studies
  • Nail Diseases and Treatments
  • Infectious Diseases and Tuberculosis
  • Bacterial Infections and Vaccines
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Cytomegalovirus and herpesvirus research

Makerere University
2023-2025

Infectious Diseases Institute
2023-2025

Abstract Background Amphotericin B is the gold standard treatment for severe mycoses. A new orally delivered, less-toxic formulation of amphotericin has been developed. Methods In our randomized clinical trial, we tested oral lipid nanocrystal (LNC) (MAT2203, Matinas Biopharma) vs intravenous (IV) human immunodeficiency virus–associated cryptococcal meningitis in 4 sequential cohorts. Two pilot cohorts assessed safety and tolerability (n = 10 each), 2 efficacy with/without IV loading doses...

10.1093/cid/ciad440 article EN cc-by Clinical Infectious Diseases 2023-08-22

Limited data exist on the antifungal activity of daily liposomal amphotericin B with flucytosine induction regimens for cryptococcal meningitis, which are recommended in high-income countries. Liposomal monotherapy at 3 mg/kg previously failed to meet noninferiority criteria compared deoxycholate its registrational clinical trial. We aimed compare quantitative and mortality between among persons human immunodeficiency virus (HIV)-related meningitis receiving adjunctive 100 mg/kg/day....

10.1093/cid/ciae326 article EN Clinical Infectious Diseases 2024-06-29

Abstract Background The EnACT trial was a phase 2 randomized clinical conducted in Uganda, which evaluated novel orally delivered lipid nanocrystal (LNC) amphotericin B combination with flucytosine for the treatment of cryptococcal meningitis. When (5FC) is used as monotherapy cryptococcosis, 5FC can induce resistant Cryptococcus mutants. Oral uses drug delivery mechanism, and we assessed whether resistance to develops during oral LNC–amphotericin therapy. Methods We enrolled Ugandans HIV...

10.1093/ofid/ofad596 article EN cc-by Open Forum Infectious Diseases 2023-11-29

Abstract Background Tuberculous meningitis (TBM) mortality averages at 27% but may reach 70% in HIV co-infection. High MRC severity grade, lower cerebrospinal fluid (CSF) white blood cell count (WBC) count, low weight, CD4 and plasma sodium were linked to Vietnam. Prognostic factors African adults with HIV-associated TBM are unknown. We sought determine the baseline predictive of death HIV-positive Ugandan TBM. Methods prospectively enrolled patients who received treatment classified as...

10.1093/ofid/ofad500.1325 article EN cc-by Open Forum Infectious Diseases 2023-11-27
Coming Soon ...